From Bluechoice Health Plan of South Carolina:

BlueChoice HealthPlan continually evaluates our prescription drug formularies and drug management programs to ensure effective management of quality and costs. We work with a group of independent doctors and pharmacists to assess our pharmacy programs and get recommendations.

CLICK HERE TO SHOP AND COMPARE HEALTH PLANS!

Based on the group’s feedback, BlueChoice® will make changes to our prescription drug coverage and Affordable Care Act (ACA) covered vaccine list. Please note, the prescription drug coverage changes only apply to BlueChoice groups using either the BlueChoice Prescription Drug List or the Tiered Prescription Drug List. They do NOT apply to groups using any other formulary.

Impacted members will be sent a notification letter in May.
Formulary Updates
These drugs will be added to the formulary effective July 1, 2022.

Exclusions
The products listed in this section have alternatives available on the formulary, many times at a lower cost to the member. Some covered alternatives may require prior authorization.

These drugs will continue as non-formulary status:
Brexafemme
Bylvay
Elyxyb
Kerendia
Livmarli
Opzelura
Rezurock
Semglee
Skytrofa
Susvimo
Tavneos
Tyrvaya
Vuity
Drugs Moving to Non-formulary Status
Effective July 1, 2022, these drugs will move to non-formulary status:
Apriso
Arava
Arimidex
Arixtra
Baraclude
Brovana
Cloderm
Elidel
Epiduo Forte
Ferriprox
Firazyr
Gleevec
Hysingla ER
Lovenox
Natroba
Noxafil
Soolantra
Soriatane
Sutent
Testim
Vagifem
Yaz

ACA Covered Vaccine Update
Effective July 1, 2022, the OptumRx* standard ACA vaccine list will be updated to include Vaxneuvance (PCV15) and Prevnar 20 (PCV20).